(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/220183 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 25/00* (2006.01)
A61P 29/00 (2006.01) *A61P 37/00* (2006.01)
A61P 11/00 (2006.01) *A61K 31/519* (2006.01)
A61P 17/06 (2006.01)

(21) International Application Number:
PCT/IB2021/053517

(22) International Filing Date:
28 April 2021 (28.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/017,679 30 April 2020 (30.04.2020) US

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventor; and
(71) Applicant *(for US only)*: **XUE, Xiaohua**; 3210 Merryfield Row, San Diego, California 92121-1126 (US).

(72) Inventors: **GOLDBERG, Steven**; 3210 Merryfield Row, San Diego, California 92121-1126 (US). **MARTIN, Connor**; 3210 Merryfield Row, San Diego, California 92121-1126 (US). **RHORER, Timothy B.**; 3210 Merryfield Row, San Diego, California 92121-1126 (US). **TANIS, Virginia M.**; 3210 Merryfield Row, San Diego, California 92121-1126 (US).

(74) Agent: **SHIRTZ, Joseph F.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17



I

(57) Abstract: The present application discloses compounds of Formula I or pharmaceutically acceptable salt thereof, wherein R^1, R^2, R^3, R^4, and R^5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

WO 2021/220183 A1